No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say

The lack of competing bids for Loxo Oncology raises questions about whether Eli Lilly could have won the deal without offering a 68% premium for the maker of targeted cancer drugs. But a closer look at the SEC documents describing the deal suggests that's not necessarily true, analysts say.